Gossamer Bio Inc (OQ:GOSS)

Business Focus: Biotechnology & Medical Research

Sector:  Healthcare Industry:  Biotechnology & Medical Research
See Regulatory Filings on SEC
Company Contact
Address: 3013 Science Park Rd
SAN DIEGO CA 92121-1101
Tel: N/A
Website: https://www.gossamerbio.com
IR: See website
Key People
Sheila Gujrathi
President, Chief Executive Officer, Co-Founder, Director
Bryan M. Giraudo
Chief Financial Officer
Christian Waage
Executive Vice President, General Counsel
Jakob Dupont
Chief Medical Officer
Luisa Salter-Cid
Chief Scientific Officer
Business Overview
Gossamer Bio, Inc. is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology. The Company has six programs: three clinical-stage product candidates and three preclinical programs. Its pipeline includes GB001, GB002, GB004, GB1275, Autoimmune program and Oncology program. GB001 is an oral antagonist of prostaglandin D2 receptor 2, or DP2, is being developed for the treatment of moderate-to-severe eosinophilic asthma and other allergic conditions. GB002 is an orally inhaled, small molecule, selective platelet-derived growth factor, or PDGF, receptor kinase inhibitor is being developed for the treatment of pulmonary arterial hypertension. GB004 is being developed for Inflammatory Bowel Disease (IBD). GB1275 is a CD11b agonist.
Financial Overview
For the six months ended 30 June 2020, Gossamer Bio Inc revenues was not reported. Net loss increased 57% to $120.9M. Higher net loss reflects In process research and development increase from $2M to $17.8M (expense), research and development increase of 24% to $70.7M (expense), Stock-based Compensation in R&D increase from $3.8M to $9.4M (expense). Basic Earnings per Share excluding Extraordinary Items decreased from -$1.23 to -$1.88.
Employees: 171 as of Feb 29, 2020
Reporting Currency: U.S. Dollars
Enterprise value: $295.42M as of Jun 30, 2020
Annual revenue (TTM): $0.00M as of Jun 30, 2020
EBITDA (TTM): -$205.45M as of Jun 30, 2020
Net annual income (TTM): -$224.14M as of Jun 30, 2020
Free cash flow (TTM): -$177.14M as of Jun 30, 2020
Net Debt Last Fiscal Year: N/A
Shares outstanding: 75,828,140 as of Aug 6, 2020
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please subscribe. Our packages start at $1.00 plus tax for the first month.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.